Expiration of warrants
Summary by AI BETAClose X
June 4, 2026
("EDX Medical" or the "Company")
Expiration of warrants
CAMBRIDGE, UK: EDX Medical Group plc (AIM: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces the expiration of all warrants over ordinary shares in EDX Medical as of 5pm yesterday, June 3rd, 2026, in accordance with the terms of the warrant instrument.
Prior to the expiration deadline, one warrant holder exercised their rights resulting in the issue of 150,000 new ordinary shares at an exercise price of 10p per ordinary share. Application has been made for 150,000 ordinary shares to be admitted to trading on AIM and it is expected that trading will commence on 9 June 2026.
Following this issue of ordinary shares the Company will have 411,994,583 ordinary shares in issue. This figure may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company or its Group under the FCA's Disclosure and Transparency Rules.
ENDS
For enquiries, please contact:
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer)
|
+44 (0)7812 345 301 |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609
|
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 20 minutes ago AVI Global Trust
- 30 minutes ago LSL Property Services
- 33 minutes ago Bluebird Merchant Ventures (DI)
- 44 minutes ago Power Probe PLC
- 45 minutes ago Origin Enterprises (CDI)